<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647893</url>
  </required_header>
  <id_info>
    <org_study_id>CTB-001</org_study_id>
    <nct_id>NCT01647893</nct_id>
  </id_info>
  <brief_title>Phase 1 Single Dose Escalation Study of CTB-001</brief_title>
  <official_title>A Phase 1 Clinical Study, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study of the Safety and Pharmacokinetic/Pharmacodynamic Profiles of CTB-001 Intravenously Administered in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chem Tech Research Incorporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chem Tech Research Incorporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Clinical Study, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose
      Escalation Study of the Safety and Pharmacokinetic/Pharmacodynamic Profiles of CTB-001
      Intravenously Administered in Healthy Male Subjects
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 7 hours</time_frame>
    <description>Summary statistics for SAD parts will be prepared for measured values and changes from baseline values for each dose group. Placebo subjects will serve as the control. Summaries of treatment-emergent and clinically important abnormalities in ECG, physical examination, vital signs, and laboratory (clinical chemistry, hematology, coagulation, urinalysis) data will be provided. The incidence of adverse events(AEs) will be tabulated and compared across dose group in the SAD parts.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTB-001</intervention_name>
    <description>IV bolus or IV infusion</description>
    <arm_group_label>CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose</arm_group_label>
    <arm_group_label>CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose</arm_group_label>
    <arm_group_label>CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose</arm_group_label>
    <arm_group_label>CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males aged 20 to 40 years at screening.

          -  Be able to understand the objective, method of the study, the characteristics of
             investigational drug, and comply with the requirement of the study. Subject must
             provide written informed consent prior to study participation.

        Exclusion Criteria:

          -  History or presence of liver, kidney, or nervous system disease, respiratory
             disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric
             or cognitive disorders.

          -  History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or
             disorders of absorption, distribution, metabolism, excretion.

          -  History of known hypersensitivity to drugs including CTB-001
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul,</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <phone>82-2-3010-4611</phone>
      <email>ksbae@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

